Abstract
Background Most tuberculosis (TB) cases in The Gambia are notified in the Greater Banjul Area (GBA). We conducted an Enhanced-Case-Finding (ECF) intervention in the GBA and determined its effect on TB incidence and ongoing TB transmission.
Methods This was a cluster randomized trial in which randomly assigned intervention areas of grouped settlements received three rounds of an ECF strategy consisting of sensitization followed by auramine microscopy, whereas TB patients in control areas continued to be identified through passive case finding. The primary outcome was TB incidence rate. To exclude that an increase in notified cases, followed by a decrease in notified cases, would hide the future impact of the intervention, we tested for changes in transmission dynamics using both genetic clustering and phylodynamic methods.
Results No significant difference in TB incidence rates, transmission clustering or effective reproductive number was detected between intervention and control areas.
Conclusion Although we did not find evidence for decreased TB incidence nor TB transmission through the ECF strategy used, this approach is an examplar of how both classical epidemiology and genomic phylodynamics approaches can be integrated to better assess public health intervention outcomes.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT01660646
Funding Statement
This work was supported by an ERC grant [INTERRUPTB; no. 311725] to BdJ and by the Global Fund for Tuberculosis, AIDS and Malaria.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
For the ECF study ethical approval was granted by the Gambia Government / MRC Joint Ethics Committee. In brief, any newly diagnosed patient initiating TB therapy at any of the Gambia Government TB diagnostic and treatment centres in the Greater Banjul Area, regardless of age, residency, HIV status, or type of TB, with permanent residence in the Greater Banjul Area was eligible for inclusion. Individuals unable to understand the implications of study participation, whether through cognitive impairment or insurmountable language barrier, were excluded from the study. For the transmission blocking study, ethical approval was provided by the Gambia Government/ MRC Joint Ethics Committee and the Institutional Review Board of the Institute of Tropical Medicine, Antwerp, Belgium. Isolates from all ECF participants (except minors, i.e., <18 years old) were included.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Raw reads are stored on the ENA under accession number PRJEB53138. Custom python scripts used for SNP clustering can be found at https://github.com/conmeehan/pathophy. XML files for BEAST analyses can be found at https://github.com/EtthelWindels/tb-ecf-gambia.
https://github.com/conmeehan/pathophy
